Some may perceive the Bridge Loan as an indication of Elite's difficulty to available financing for its business operations. On the contrary, when CEO Jerry Treppel increased a line of credit for an addtional $500K, then we have a CEO who is result-driven and will not have any financial obstacles impede Elite's progress to proceed with its drug pipeline development. Cheers!
Full disclosure here. There's no question that the issuance of that patent has piqued the industry's interest. Okay? And we know that from the calls that we get.
But, as I said before, piquing interest is not the same thing as I want to sit down and discuss terms with you. And we think in order for that to happen, as Chris just said, you have got to demonstrate to people that I can commercially make -- scale it up; I've done the biostudies; I have a product. Okay? And that's our goal, and we will get there in this fiscal year.